NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study

NCT07743996

RecruitingN/A

Sponsor: Boehringer Ingelheim

Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

Countries: Japan

This is a cross-sectional study that will be conducted across Japan using an online patient-reported outcome questionnaire. This study tries to find out the attitudes toward and experiences of the emotional and/or social impact of side effects associated with antifibrotic (AF) treatment among Japanese patients with Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF), and how are these attitudes associated with patients' individual characteristics.

Eligibility overview

Sex: ALL

Age: 40 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Patients with IPF aged 40 years or older who received nintedanib or pirfenidone within the previous 4 weeks, or patients with PPF aged 18 years or older who received nintedanib within the previous 4 weeks
2. Patients capable of responding to a self-administered questionnaire

Exclusion Criteria:

1. Patients treated with nerandomilast (including clinical trials)
2. Patients with PPF treated with pirfenidone
3. Patients currently hospitalized
4. Patients with malignant tumors

Locations (1)

Tokyo, Japan